Published: May 18, 2010
Updated: May 18, 2010
Reporters & producers can visit Duke Medicine News and Communications for contact information.
By Duke Medicine News and Communications
When the forces of evolution took over an experimental strain of bacteria, it derailed an experiment Duke and North Carolina State University researchers thought they were conducting, but led to something much more profound instead.
The researchers used a colony of mice raised in a large plastic bubble, called an isolator, that was completely sterile, lacking even a single bacterium. They introduced a single type of bacteria into the mouse colony, but it mutated quickly into different types, making new bacteria that were hardier inside of the mice than the original bacterium was.
“In some regards, this is one of the best demonstrations of evolution ever carried out in a laboratory,” said William Parker, PhD, assistant professor in the Duke Department of Surgery. "This is the first time the evolution of bacteria has been monitored for a period of years in an incredibly complex environment.”
Parker said the work illustrates the power of evolution in creating diversity and in filling ecological niches. “This study also strengthens the idea that we could harness evolution in the laboratory to develop microbes for use in biotechnology and in medicine,” Parker said.
The results, which appear in the journal Applied and Environmental Microbiology, indicate that “experimental evolution,” or evolution controlled in a laboratory setting, could be used to develop new strains of bacteria for use as probiotic substances, which are living organisms used for intestinal and digestive therapies.
The scientists put a single strain of bacteria, brushed onto the mice, in a colony of otherwise bacteria-free mice. The study bacteria were engineered to make a structure (called a type 1 pilus) that helps them stick to things. The researchers hoped to learn how the molecule would affect the interaction between the bacteria and the mice.
“We were surprised, because we thought we would be able to study this engineered bacterium for a while, but we were wrong,” Parker said. The bacteria started to mutate and quickly lost the pilus structure that had been engineered into them. The single homogeneous strain was rapidly evolving into a diverse community of organisms.
“We did a variety of experiments to rule out contamination as the source of the diversity,” Parker said. “It became clear that evolution was messing up our experiment. At that point, because the evolutionary process seemed to be driving the bacteria to live more effectively in the mouse gut, and because developing bacteria to live more effectively in the gut is one of our primary goals, we decided to let the process run and see where it would go.”
Over the three-year study period, the bacterial population remained diverse and appeared to adapt significantly well to the environment in the digestive tracts of the mice. “The bacteria colonized better in the mice by the end of the experiment than at the beginning,” Parker said, with more than a three-fold increase in the density of bacteria within the gut by the end of the experiment.
“We see a number of evolutionary adaptations occurring in the bacteria, including a potential increase in resistance to cell death,” Parker said. One future goal of the research is to understand the genetic changes responsible for the adaptations.
A large team composed of scientists from Duke and from North Carolina State University was involved in the study, which took place over the course of about seven years, including preparation prior to the three years in the isolator and the analyses of the bacteria afterward.
The team included Sean M. Lee, Aaron Wyse, Aaron Lesher, Mary Lou Everett, Linda Lou, Zoie E. Holzknecht, John F. Whitesides, Dawn E. Bowles, Shu S. Lin, and R. Randal Bollinger from Duke, and Susan L. Tonkonogy, Paul E. Orndorff, Patricia A. Spears, and Donna Kronstadt from North Carolina State.
The work was funded by the National Institutes of Health through the Center for Gastrointestinal Biology and Disease and the Duke Human Vaccine Institute Flow Cytometry Core Facility.